全球生物模擬市場規模、佔有率、成長分析、依應用（藥物開發、藥物發現）、最終用戶（製藥和生物技術公司、學術機構和研究實驗室）- 2024-2031 年產業預測

Global Biosimulation Market Size, Share, Growth Analysis, By Application(drug development, drug discovery), By End user(pharmaceutical and biotechnology companies, academic institutes and research laboratories) - Industry Forecast 2024-2031

出版日期: 2024年04月27日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球生物模擬市場規模為28.1億美元，預計將從2023年的32.8億美元成長到2031年的114.6億美元，在預測期間（2024-2031年）複合年成長率為16.90%。

生物模擬利用電腦程式模擬生物過程，透過預測未來的實驗結果，在藥物發現和開發中找到了多種應用。考慮到後期藥物開發涉及的巨大成本和資源，它在預測藥物分子的功效和潛在失敗方面的作用至關重要。特別值得注意的是，在 COVID-19 大流行期間，其需求激增，其在疫苗開發中的關鍵作用證明了這一點。例如，領先的生物模擬技術公司 Certara 迅速調整其服務以協助疫苗開發商，強調了對生物模擬工具的高度依賴來應對藥物開發課題，從而推動市場成長。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 歐洲其他地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 拉丁美洲其他地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- MEA 的其餘部分

競爭格局

前 5 名企業比較
2023 年關鍵參與者的市場定位
主要市場參與者所採取的策略
最佳制勝策略
近期市集活動
主要公司市佔率 (%), 2023

主要公司簡介

Certara
Dassault Systemes SE
Simulations Plus Inc.
Schrodinger Inc.
Physiomics Plc
Advanced Chemistry Development Inc.
In silico biosciences Inc.
Genedata AG
Evidera Inc.
Leadscope Inc.
Insilico Biotechnology AG
Rhenovia Pharma SAS
Entelos Inc.
Biocomputing Platforms Ltd.
Rosa & Co. LLC
Genedata AG
OpenEye Scientific Software Inc.
Nexelis
Compugen Ltd.
Chemical Computing Group ULC

簡介目錄

Product Code: SQMIG35I2104

Global Biosimulation Market size was valued at USD 2.81 billion in 2022 and is poised to grow from USD 3.28 billion in 2023 to USD 11.46 billion by 2031, growing at a CAGR of 16.90% during the forecast period (2024-2031).

Biosimulation, utilizing computer programs to simulate biological processes, finds diverse applications in drug discovery and development by enabling prediction of future outcomes of experiments. Its role in foreseeing the efficacy and potential failures of drug molecules is crucial, given the immense costs and resources involved in late-stage drug development. Particularly notable is its surge in demand during the COVID-19 pandemic, as evidenced by its pivotal role in vaccine development. For instance, Certara, a leading biosimulation technology company, swiftly adapted its services to assist vaccine developers, underscoring the heightened reliance on biosimulation tools to navigate drug development challenges, thereby fueling market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biosimulation Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biosimulation Market Segmental Analysis

The global biosimulation market is divided into three sections: offering type, application, and end user. The market is classified into two types of offerings: software and services. The software segment is divided into the following categories: PK/PD modelling and simulation, PBPK modelling and simulation, trial simulators, molecular modelling, and others. The Biosimulation Market is classified into three applications: drug discovery, drug development, and others. End users in the Biosimulation Market include contract research organisations, pharmaceutical and biotechnology companies, research institutes, regulatory institutes, and others. By region, the Biosimulation Market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Biosimulation Market

The global biosimilars market is witnessing growth propelled by multiple factors. These include the mounting imperative to reduce healthcare expenditures, heightened interest in cost-effective biosimilars, escalating incidence rates of diverse diseases, expanding array of off-patent drugs, promising outcomes from ongoing clinical trials, and surging demand for biosimilars across therapeutic domains like rheumatoid arthritis and blood disorders.

Restraints in the Global Biosimulation Market

The utilization of biosimulation technologies in drug discovery and development lacks standardization, employing various models and techniques to register and process diverse biological events. Due to the heightened complexity, storing, modifying, and sharing data and models pose challenges for researchers. Standardization is essential to ensure the production of dependable and efficient outcomes. However, the absence of standards from regulatory authorities stands as a major impediment to the expansion of the biosimulation industry.

Market Trends of the Global Biosimulation Market

A primary factor propelling market expansion is the escalating occurrence of drug relapse incidents linked to drug resistance in ailments like cancer, tuberculosis, and bacterial infections. Furthermore, the market is influenced by heightened governmental funding aimed at fostering the uptake of these remedies. Moreover, the biosimulation sector gains from augmented healthcare expenditure, enhancements in healthcare infrastructure, and a growing demand for comprehensive care provision.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Biosimulation Market by Application

Market Overview
drug development
drug discovery
and others

Global Biosimulation Market by End user

Market Overview
pharmaceutical and biotechnology companies
academic institutes and research laboratories
contract research organisations
and others

Global Biosimulation Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Certara
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dassault Systemes SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Simulations Plus Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Schrodinger Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Physiomics Plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Advanced Chemistry Development Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
In silico biosciences Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genedata AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Evidera Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Leadscope Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Insilico Biotechnology AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Rhenovia Pharma SAS
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Entelos Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocomputing Platforms Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Rosa & Co. LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genedata AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OpenEye Scientific Software Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nexelis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Compugen Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chemical Computing Group ULC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments